The pharmaceutical community is excited by retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing remarkable results in clinical studies . This treatment works by replicating natural hormones to affect appetite and boost feelings of fullness , ultimately resulting in considerable wei